Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function

Experimental Neurology

Volumn 180, Issue 1, 2003, Pages 74-87

  Robinson, Siobhan ^a,c   Freeman, Pierre ^b   Moore, Cynthia ^b   Touchon, Justin C ^b   Krentz, Lisa ^b   Meshul, Charles K ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Electron microscopy; Glutamate synapses; Immunocytochemistry; In vivo microdialysis; MPTP; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; NEUROTOXIN; RECEPTOR SUBUNIT; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; EXTRACELLULAR SPACE; INJECTION; MALE; MOUSE; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; ULTRASTRUCTURE; ACUTE DISEASE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; METABOLISM; MICRODIALYSIS; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; SYNAPTOSOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; MICROSCOPY, IMMUNOELECTRON; PARKINSON DISEASE, SECONDARY; PRESYNAPTIC TERMINALS; PROTEIN SUBUNITS; RECEPTORS, GLUTAMATE; SYNAPSES; TYROSINE 3-MONOOXYGENASE;

EID: 0037349708     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(02)00050-X     Document Type: Article

References (74)

1. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of Parkinsonism. J. Neurophysiol. 72:1994;507-520.
2. Betarbet R., Porter R.H.P., Greenamyre J.T. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J. Neurochem. 74:2000;1166-1174.
3. Bevan M.D., Wilson C.J. Mechanisms underlying spontaneous oscillation and rhythmic firing in rat subthalamic neurons. J. Neurosci. 19:1999;7617-7628.
4. Bouyer J.J., Park D.H., Joh T.H., Pickel V.M. Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum. Brain Res. 302:1984;267-275.
5. Brotchie J.M., Mitchell I.J., Sambrook A., Crossman A.R. Alleviation of Parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Dis. 6:1991;133-138.
6. Brouillet E., Beal M.F. NMDA antagonists partially protect MPTP induced neurotoxicity in mice. NeuroReport. 4:1993;387-390.
7. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet R.J., Bedard P.J., Di Paolo T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuro-Psychopharm. & Biol. Psychiat. 26:2002;127-138.
8. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
9. Chan P., Monte D.A., Langston J.W. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain. Brain Res. 647:1994;249-254.
10. Chan P., Di Monte D.A., Langston J.W., Janson A.M. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. Exp. Neurol. 280:1997;439-446.
11. + elimination in the mouse striatum. J. Pharmacol. Exp. Pharmacol. 267:1993;1515-1520.
12. + in astrocytic cultures. Toxicol. Appl. Pharmacol. 158:1999;296-302.
13. 2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 264:1993;221-225.
14. Dube L., Smith A.D., Bolam J.P. Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J. Comp. Neurol. 267:1988;455-471.
15. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57:2000;342-352.
16. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588.
17. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego.
18. Fredriksson A., Gentsch C., Archer T. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice. J. Neural Transm. 97:1994;197-209.
19. Fredriksson A., Palomo T., Chase T., Archer T. Tolerance to a suprathreshold dose of L-dopa in MPTP mice effects of glutamate antagonists . J. Neural Transm. 106:1999;283-300.
20. Ganguly A., Keefe K.A. Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience. 103:2001;405-412.
21. Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., Riederer R. A post mortem study on neurochemical markers of dopaminergic, GABAergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. 741:1996;142-152.
22. Godukhin O.V., Zharikova, A.D. Yu. Budantsev, A., 1984. Role of presynaptic dopamine receptors in regulation of the glutamatergic neurotransmission in rat neostriatum. Neuroscience 12, 377-383.
23. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:1994;655-661.
24. He L., Di Monte D.A., Langston J.W., Quik M. Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and levodopa treatment . Neuroscience. 99:2000;697-704.
25. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
26. Hepler J.R., Toomim C.S., McCarthy K.D., Conti F., Battaglia G., Rustioni A., Petrusz P. Characterization of antisera to glutamate and aspartate. J. Histochem. Cytochem. 36:1988;13-22.
27. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
28. Jonkers N., Sarre S., Ebinger G., Michotte Y. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 926:2002;149-155.
29. Kerkerian L., Dusticier N., Nieoullon A. Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J. Neurochem. 48:1987;1301-1306.
30. Klockgether T., Turski L., Honore T., Zhang Z., Gash D.M., Kurlan R., Greenamyre J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:1991;717-723.
31. Kopin I.J., Markey S.P. MPTP toxicity implication for research in Parkinson's disease . Annu. Rev. Neurosci. 11:1988;81-96.
32. Kozell L.B., Meshul C.K. The effects of acute cocaine or sensitization to cocaine on nerve terminal glutamate within the rat mesolimbic system. Neuroscience. 106:2001;15-25.
33. Kupsch A., Loschmann P.-A., Sauer H., Arnold G., Renner P., Pufal D., Burg M., Wachtel H., ten Bruggencate G., Oertel W.H. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 592:1992;74-83.
34. Lindefors N., Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci. Lett. 115:1990;248-252.
35. Loschmann P.-A., Lange K.W., Kunow M., Rettig K.-J., Jahnig P., Honore T., Turski L., Wachtel H., Jenner P., Marsden C.D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J. Neural Transm. 3:1991;203-213.
36. Magill P.J., Bolam J.P., Bevan M.D. Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network. Neuroscience. 106:2001;313-330.
37. Maura G., Giardi A., Raiteri M. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J. Pharmacol. Exp. Ther. 247:1988;680-684.
38. McGeorge A.J., Faull R.L.M. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
39. Meshul C.K., Allen C. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion. Synapse. 36:2000;129-142.
40. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K. Time-dependent changes in striatal glutamate synapses following a 6-OHDA lesion. Neuroscience. 88:1999;1-16.
41. Meshul C.K., Kamel D., Moore C., Kay T.S., Krentz L. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA lesioned rats. Exp. Neurol. 175:2002;257-274.
42. Meshul C.K., Stallbaumer R.K., Taylor B., Janowsky A. Haloperidol-induced synaptic changes in striatum are associated with glutamate synapses. Brain Res. 648:1994;181-195.
43. Michel P.P., Agid Y. The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures. Brain Res. 597:1992;233-240.
44. 3H]glutamic acid release by dopaminergic drugs. Life Sci. 26:1980;2073-2081.
45. Morari M., O'Connor W.T., Ungerstedt U., Bianchi C., Fuxe K.J. Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat. II. Evidence for striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function. Neuroscience. 72:1996;89-97.
46. 2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. Eur. J. Pharmacol. 256:1994;23-30.
47. O'Dell S.J., Marshall J.F. Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury. NeuroReport. 7:1996;2457-2461.
48. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
49. Phend, K.D., Weinberg, R.J., Rustioni, A., 1992. Techniques to optimize post-embedding single and double staining for amino acid neurotransmitters. J. Histochem. Cytochem. 40, 1011-1020.
50. Pierce, R.C., Bell, K., Duffy, P., Kalivas, P.W., 1996. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J. Neurosci. 16, 1550-1560.
51. Porter R.H.P., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral DA depletion. J. Neurosci. 14:1994;7192-7199.
52. Ricaurte G.A., Langston J.W., Delanney L.E., Irwin I., Peroutka S.J., Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine a neurochemical and morphological reassessment . Brain Res. 376:1986;117-124.
53. Robinson T.E., Wishaw I.Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra a microdialysis study in freely moving rats . Brain Res. 450:1988;209-224.
54. Rowlands G.J., Roberts P.J. Activation of dopamine receptors inhibits calcium-dependent glutamate release from corticostriatal terminals in vitro. Eur. J. Pharmacol. 62:1980;241-242.
55. Salin P., Hajji M.D., Kerkerian-LeGoff L. Bilateral 6- hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur. J. Neurosci. 8:1996;1746-1757.
56. + neurotoxicity by N-methyl-D-aspartate antagonists. Brain Res. 586:1992;203-207.
57. Schuster R. Determination of amino acids in biological, pharmaceutical, plant and food samples by automated precolumn derivatization and high-performance liquid chromatography. J. Chromatogr. 431:1988;271-284.
58. 2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J. Neurosci. 14:1994;88-106.
59. Silverdale M.A., Crossman A.R., Brotchie J.M. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned Macaque model of Parkinson's disease and dyskinesia. Exp. Neurol. 174:2001;21-28.
60. Smith Y., Bennett B.D., Bolam J.P., Parent A., Sadikot A.F. Synaptic relationship between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum of the monkey. J. Comp. Neurol. 334:1994;1-19.
61. Sonsalla P.K., Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129:1986;339-345.
62. Sonsalla P.K., Zeevalk G.D., Manzino L., Giovanni A., Nicklas W.J. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic MPTP in mice or intranigral MPTP in rats. J. Neurochem. 58:1992;1979-1982.
63. +) nigral toxicity in the rat by prior decortication or MK-801 treatment a stereological estimate of neuronal loss . Neurobiol. Aging. 14:1993;295-301.
64. Starr M.S. Antiparkinsonian actions of glutamate antagonists - alone and with L-DOPA a review of evidence and suggestions for possible mechanisms . J. Neural Transm. [P-D Sect]. 10:1995;141-185.
65. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
66. + produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58:1992;1975-1978.
67. Tabatabaei A., Perry T.L., Hansen S., Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci. Lett. 141:1992;192-194.
68. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transerase labelling and acridine orange staining. Neuroscience. 77:1997;1037-1048.
69. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
70. +-induced dopamine overflow in the striatum of freely moving C57BL/6 mice. J. Neural Transm. 108:2001;899-908.
71. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release possible role in neurotoxicity and tardive dyskinesia . Brain Res. 788:1998;215-222.
72. +- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens. Life Sci. 67:2000;241-250.
73. Wullner U., Brouillet E., Isacson O., Young A.B., Penney J.B. Glutamate receptor binding sites in MPTP-treated mice. Exp. Neurol. 121:1993;284-287.
74. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58:1992;1736-1742.